追蹤
Bjorn T. Gjertsen
Bjorn T. Gjertsen
Professor of Hematology, University of Bergen
在 uib.no 的電子郵件地址已通過驗證 - 首頁
標題
引用次數
引用次數
年份
Single cell profiling of potentiated phospho-protein networks in cancer cells
JM Irish, R Hovland, PO Krutzik, OD Perez, Ø Bruserud, BT Gjertsen, ...
Cell 118 (2), 217-228, 2004
8712004
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
C Gjerdrum, C Tiron, T Høiby, I Stefansson, H Haugen, T Sandal, K Collett, ...
Proceedings of the National Academy of Sciences 107 (3), 1124-1129, 2010
6582010
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia
T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ...
Cancer discovery 3 (12), 1416-1429, 2013
461*2013
A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer
G Dimcevski, S Kotopoulis, T Bjånes, D Hoem, J Schjøtt, BT Gjertsen, ...
Journal of Controlled Release 243, 172-181, 2016
4312016
The protein phosphatase inhibitor okadaic acid induces morphological changes typical of apoptosis in mammalian cells
R Bøe, BT Gjertsen, OK Vintermyr, G Houge, M Lanotte, SO Døskeland
Experimental cell research 195 (1), 237-246, 1991
4011991
Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis
ED Lynch, EA Ostermeyer, MK Lee, JF Arena, HL Ji, J Dann, K Swisshelm, ...
The American Journal of Human Genetics 61 (6), 1254-1260, 1997
3541997
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients
S Berentsen, E Ulvestad, BT Gjertsen, H Hjorth-Hansen, R Langholm, ...
Blood 103 (8), 2925-2928, 2004
3422004
Novel (Rp)-cAMPS Analogs as Tools for Inhibition of cAMP-kinase in Cell Culture: BASAL cAMP-KINASE ACTIVITY MODULATES INTERLEUKIN-1β ACTION (∗)
BT Gjertsen, G Mellgren, A Otten, E Maronde, HG Genieser, B Jastorff, ...
Journal of Biological Chemistry 270 (35), 20599-20607, 1995
2711995
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
RJ Kreitman, C Dearden, PL Zinzani, J Delgado, L Karlin, T Robak, ...
Leukemia 32 (8), 1768-1777, 2018
2682018
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
MV Mateos, H Blacklock, F Schjesvold, A Oriol, D Simpson, A George, ...
The Lancet Haematology 6 (9), e459-e469, 2019
2422019
SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells
L Li, T Osdal, Y Ho, S Chun, T McDonald, P Agarwal, A Lin, S Chu, J Qi, ...
Cell stem cell 15 (4), 431-446, 2014
2422014
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
BT Gjertsen, P Schöffski
Leukemia 29 (1), 11-19, 2015
2222015
The genetic subtypes of cAMP-dependent protein kinase—functionally different or redundant?
SO Døskeland, E Maronde, BT Gjertsen
Biochimica Et Biophysica Acta (BBA)-Molecular Cell Research 1178 (3), 249-258, 1993
2121993
Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells
O Bruserud, C Stapnes, E Ersvaer, BT Gjertsen, A Ryningen
Current pharmaceutical biotechnology 8 (6), 388-400, 2007
1912007
Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial
C Gjerde, K Mustafa, S Hellem, M Rojewski, H Gjengedal, MA Yassin, ...
Stem cell research & therapy 9, 1-15, 2018
1862018
Ultrarapid caspase-3 dependent apoptosis induction by serine/threonine phosphatase inhibitors
KE Fladmark, OT Brustugun, R Hovland, R Bøe, BT Gjertsen, ...
Cell Death & Differentiation 6 (11), 1099-1108, 1999
1701999
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells
Ø Bruserud, A Ryningen, AM Olsnes, L Stordrange, AM Øyan, KH Kalland, ...
Haematologica 92 (3), 332-341, 2007
1502007
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
H Kuusanmäki, AM Leppä, P Pölönen, M Kontro, O Dufva, D Deb, ...
Haematologica 105 (3), 708, 2019
1482019
The proteasome inhibitors bortezomib and PR‐171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells
C Stapnes, AP Døskeland, K Hatfield, E Ersvær, A Ryningen, JB Lorens, ...
British journal of haematology 136 (6), 814-828, 2007
1472007
Favourable response to therapy with the anti‐CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease
S Berentsen, GE Tjønnfjord, R Brudevold, BT Gjertsen, R Langholm, ...
British Journal of Haematology 115 (1), 79-83, 2001
1462001
系統目前無法執行作業,請稍後再試。
文章 1–20